[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fioversol.html[/a] <br> <br>#Ioversol <br> <br>Ioversol <br>CAS No.: 87771-40-2 <br>Molecular formula: C18H24I3N3O9 <br>Molecular Weight: 807.11 <br>Quality standard: CP, USP <br>Characteristics: White or almost white powder <br>Content (HPLC): ≥99.0% <br>Packing: 25KG, 50KG/drum <br>Storage: Protected from light, sealed tightly <br> <br>If you need any kinds of contrast medium, please contact us, as a professional contrast media manufacturing companies, Bei lu is willing to offer you high quality products.

[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiopamidol-intermediate.html[/a] <br> <br>#Beilu <br> <br>CAS No.: 35453 19 1 <br>Molecular formula: C8H4I3NO4 <br>Molecular weight: 558.84 <br>Quality standard: CP, USP <br>Content (HPLC): ≥99.0% <br>Packing: 25KG, 50KG/drum <br>Storage: Protected from light, sealed tightly <br> <br>Beilu, as an excellent contrast media manufacturer, offers a wide range of ct contrast media for you to choose from.

#iopamidol #370 <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiopamidol-injection.html[/a] <br> <br> <br>Iopamiro injection is the second-generation non-ionic iodinated Contrast Media launched in the global market. In 2015, Beilu firstly launched and listed iopamidol 370 Injection, one of the most widely used types of contrast medium in the Chinese market.  <br>Product name: Iopamidol Injectionnon <br>Generic name: Iopamidol Injection <br>Type: Injectable Contrast Media for CT/X-ray <br>Ingredients: Iopamidol <br>Specification: <br>(1) 50ml: 15 gl <br>(2) 100ml: 30 gl <br>(3) 50ml: 18.5 gl <br>(4) 100ml: 37 gl <br>Administration: Intravascular injection <br>Adverse reactions: The application of organic iodine compounds can cause adverse reactions, as well as allergic or drug-induced shock. See the details from the package insert <br>Shelf life: 36 months <br> <br>Advantages of iopamidol 300 Injection <br>High enhancement value, which increased the contrast between the lesion and solid organs, improved the lesion detection. <br>Low viscosity <br>Low osmotic pressure <br>Low injection speed, which reduces vascular pressure and prevents contrast media extravasation (patient with poor tolerance, such as children, elderly, diabetes or tumor patients, are more suitable for high-concentration contrast media) <br>The low total dosage of Contrast media <br>Low radiation dose <br> <br>Indications of Iopamidol Injection <br>Neuroradiology: Spinal nerve root angiography, Cisternography and ventriculography. <br>Angiography: Cerebral arteriography, Coronary angiography, Thoracic aorta and abdominal aorta angiography, Angiocardiography, Selectivevisceral arteriography, Peripheral arteriography and venography, Digital subtraction angiography of cerebral arteries, peripheral arteries and abdominal arteries. <br>Urinary system angiography: Venous urography, Enhanced scan in CT examination, Arthrography, Fistula angiography, Digital subtraction angiography. <br>Precautions please refer to the package insert.

#visipaque #package #insert <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fiodixanol-injection.html[/a] <br> <br>Iodixanol Injection is a visipaque contrast media that is isotonic with plasma. It has excellent cardiac safety and renal safety, which is most comfortable to use, especially suitable for high risk patients. Gadopentetate iodixanol visipaque is also available here. <br> <br>Product name: Iodixanol Injection <br>Generic name: Iodixanol Injection <br>Type: visipaque package insert for CT/X-ray <br>Ingredients: visipaque 320 <br>Specification: <br>(1)100ml-27 gl <br>(2)50ml-16 gl <br>(3)100ml-32 gl <br>Administration: For Intravascular use only <br>Adverse reactions: See the details from the package insert <br>Shelf life: 24 months <br> <br>Beilu also produces visipaque package insert with high quality and reasonable price, contact us for more info!

Since Gadopentetate Dimeglumine Injection was launched in 1992 by Beilu Pharma in China, it was highly recommended and accepted by the radiologist, and quickly occupied the market with its excellent quality and reasonable price. Up to now, linear gadolinium has been safely used for nearly 30 years, with excellent enhancement effects and few side effects. Beilu also produces gadobutrol injection with high quality and reasonable price, contact us for more info! <br> <br>Product name: Gadopentetate Dimeglumine Injection <br>Generic name: Gadopentetate Dimeglumine Injection <br>Type: Injectable Contrast Media for MRI, Linear Contrast Media <br>No.1 market share in China <br>Ingredients: Gadopentetate Dimeglumine <br>Specification: 10ml:4.69 g; 12ml:5.63 g; 15ml:7.04 g; 20ml:9.38 g <br>Posology and method of administration: Intravenous injection <br>Adverse reactions: See the details from the package insert <br>Shelf life: 36 months <br> <br>Indication of Gadopentetate Dimeglumine Injection <br>Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues. <br>Precautions of Gadopentetate Dimeglumine Injection <br>1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies. <br>2. Take care to avoid the extravasation of the gadopentetic acid liquid during injection to prevent tissue pain. <br>3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours. <br>4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk. <br>5. The effective enhancement time of Magnevist contrast is 45 minutes. MRI examination should be performed immediately after intravenous injection. <br>6. The remaining medicine liquid after one examination should not be used again. <br>7. When applying this type of MRI contrast media, follow the relevant safety regulations in magnetic resonance imaging. <br>8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible. <br>9. Gadolinium deposition <br>Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic. <br>The clinical significance of brain gadolinium deposition is unclear. <br>In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration. <br>#Gadopentetate#Dimeglumine#Injection <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fgadopentetate-dimeglumine-injection-api%2F[/a]

In 2020, Beilu launched its macrocyclic Contrast Media- Gadobutrol Injection, it is gadolinium-based non-ionic Contrast Media, a paramagnetic Contrast Media used in various parts of the body lesion (including the brain and spinal cord) MRI imaging and angiography examination. Its macrocyclic nature ensures it is well-tolerated with a good safety profile for MRI Contrast. As a professional contrast media manufacturer, Beilu can provide you with the high concentration gadobutrol gadovist that leads to a better image with lower volume. We also provide DTPA acid with high quality. <br> <br>Product name: Gadobutrol Injection <br>Generic name: Gadobutrol Injection <br>Type: Injectable Contrast Media for MRI, Macrocyclic Contrast Media <br>Ingredients: Gadobutrol <br>Specification: gadovist 7.5 ml : 4.5354 g <br>Administration: Intravenous administration only. <br>Adverse reactions: See the details from the package insert. <br>Shelf life: 24 months <br> <br>Indication of Gadopentetate Dimegumine Injection <br>Magnetic resonance imaging of the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs and other human organs and tissues. <br> <br>Precautions of Gadopentetate Dimegumine Injection <br>1. Use with caution in patients with severe kidney damage, epilepsy, hypotension, asthma and other allergic respiratory diseases and those with allergic tendencies. <br>2. Pay attention to avoid the extravasation of the liquid during the gadobutrol injection uses so as to prevent tissue pain. <br>3. The serum iron and bilirubin levels of some patients will increase slightly after medication, but they are asymptomatic and can return to normal within 24 hours. <br>4. Pregnant women and breastfeeding women should use it with caution. Animal experiments show that a small amount of medicine liquid enters the milk. <br>5. The effective enhancement time of this product is 45 minutes. MRI examination should be performed immediately after intravenous injection. <br>6. The remaining medicine liquid after one examination should not be used again. <br>7. When applying the gadovist dose, follow the relevant safety regulations in magnetic resonance imaging. <br>8. GBCAs should be used with caution. When plain scan MRI cannot obtain the corresponding vital diagnostic information, GBCAs can be used, and the lowest approved dose is used as much as possible. <br>9. Gadolinium deposition <br> <br>Current evidence shows that after repeated use of GBCAs, trace amounts of gadolinium can remain in the brain and other body tissues. Research reports have shown that multiple uses of GBCAs can increase the intensity of brain signals, especially in the dentate nucleus and globus pallidus. Currently, there are more reports about linear GBCAs and fewer reports about macrocyclic GBCAs. Animal experiments have shown that the amount of gadolinium deposited after repeated use of linear GBCAs is higher than that of repeated use of macrocyclic. <br>The clinical significance of brain gadolinium deposition is unclear. <br>In order to minimize the potential risks associated with gadolinium deposition in the brain, it must be used in strict accordance with the indications and approved doses. It is recommended to use the lowest approved dose that meets the requirement of diagnosis and perform a careful benefit-risk assessment and patient informed communication before repeated administration. <br>#gadobutrol#injection#uses <br>[a]https%3A%2F%2Fwww.beilupharma.com%2Fproducts%2Fgadobutrol-Injection-api.html[/a]